FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2035662303> ?p ?o ?g. }

• W2035662303 endingPage "104" @default.
• W2035662303 startingPage "104" @default.
• W2035662303 abstract "Dear Editor:The efficacy of ultraviolet A1 (UVA1, 340~400 nm) in the treatment of mycosis fungoides (MF) appears to be equal to or better than psoralen UVA (PUVA), and may be more effective for nodular and thick plaque lesions1. There are several reports regarding the effectiveness of UVA1 for MF1,2. However, no study to date in Asians has described the patient response to UVA1 therapy for the treatment of MF according to a low-, medium-, or high-dose regimen.Fourteen patients with histologically proven MF (9 males, 5 females, mean age 43.8 years, age range 14~67 years) were enrolled in this study. The duration of diseases ranged from 2 months to 10 years (mean, 4.2 years). Ten patients (71.4%) had stage IA, 3 (21.4%) had stage IB, and 1 (7.1%) had stage IVB of the TNM staging system.Patients were treated with low-dose (20 J/cm2), medium-dose (65 J/cm2) or high-dose (100 J/cm2) UVA1. The UVA1 therapy was delivered by a SELLAMED 3000® (Sellas Medizinische Gerate GmbH, Gevelsberg, Germany). The main wavelengths were emitted from 340 nm to 400 nm. The irradiation intensity was 70 mW/cm2. The frequency of therapy was 3 to 5 times per week.Clinical response was graded as complete response (CR, 95~100%), partial response (PR, 50~95%), and no response (<50%). Biopsies were taken after treatment in 5 of 14 patients.Three patients were treated with low-dose UVA1 therapy. CR was observed in 3 patients (100%). None of the 3 patients with CR relapsed over a median period of 62 months after treatment.Seven patients were treated with medium-dose UVA1. Of the 7 patients, CRs and PRs were achieved in six (85.7%), and one (14.3%) patient, respectively. One of the 6 patients with CR relapsed after 30 months. The patient that relapsed achieved a CR after an additional 14 irradiations with medium-dose UVA1, and did not relapse for 34 months. None of the 5 patients with CR relapsed over a median period of 35 months after treatment.Four patients were treated with high-dose UVA1. Two patients exhibited a CR and 2 patients had a PR. In 1 of the 2 patients with CR, the skin lesions relapsed. The relapsed patient showed a CR after 39 treatment sessions of UVA1, but the skin lesions relapsed after another 6 months. This patient again achieved a CR after 11 more irradiations with high-dose UVA1 and did not relapse for 35 months. The other patient who exhibited CR did not relapse at a follow-up of 33 months. Among the 14 patients with MF treated in our study, CRs and PRs were observed in 11 (78.5%) and 3 (21.5%) patients, respectively (Fig. 1). The mean number of treatments in patients with a CR was 22.0 within a mean time of 41.3 months (range, 2~120 months). In this study, CR was observed between 9 and 50 exposures regardless of the dosages of UVA1. In low-dose UVA1 therapy, CR was observed in all 3 patients after a mean number of 16.7 UVA1-irradiations. In medium-dose UVA1 therapy, CR was observed in 6 patients after a mean number of 24.2 UVA1-irradiations. In high-dose UVA1 therapy, CR was observed in 2 patients after a mean number of 36 UVA1-irradiations.Fig. 1(A) Clinical feature of a patient with mycosis fungoides palmaris et plantaris before treatment (case 1). (B) Complete response of active disease after 13 treatments with low-dose ultraviolet A1.During patient follow-up (range 21 to 88 months), only 2 of 14 patients relapsed. The 2 relapsed patients responded faster to a second course of UVA1 therapy than the first treatment suggesting that acute lesions quickly responded to UVA1 therapy.Five patients were evaluated histopathologically after completed treatment. CRs and PRs were observed in 4 and 1 patients, respectively. No serious adverse effects were observed except for hyperpigmentation (Table 1).Table 1Characteristics and clinical response of patients with mycosis fungoides treated with UVA1 therapyCurrently, phototherapy is a main treatment option in early stage MF. In a meta-analysis study, CR rates ranged from 54% to 91% in patients with MF treated with narrowband ultraviolet B1 (NB-UVB) or PUVA3.In addition, UVA1 phototherapy also has a favorable and fast therapeutic effectiveness in localized thick and nodular lesions. Our study showed a 78.5% overall complete remission rate. The effectiveness of UVA1 can be related to its penetration depth and ability to mediate different forms of apoptosis. Specifically, UVA1 penetrates deeper than PUVA and NB-UVB4,5. Thus, the duration of CR by UVA1 is typically shorter than PUVA and NB-UVB for palmar or plantar MF. In addition, UVA1 can induce both a protein synthesis dependent (programmed cell death) and protein synthesis independent (pre-programmed cell death) apoptotic mechanism6,7. Furthermore, UVA1 phototherapy has no adverse effect of psoralen sensitization.Plettenberg et al.2 demonstrated that medium and high-dose UVA1 phototherapy leads to complete clearance. In another study, one patient with MF (stage III) showed marked improvement after 15 sessions of medium-dose UVA18. These results showed medium-dose UVA1 is sufficient to induce marked apoptosis in dermal T-cells.Zane et al.1 reported that 11 of 13 patients treated with high-dose UVA1 showed CR, with 7 of the patients who exhibited a CR not experiencing recurrence during a mean follow-up of 7.2 months, while the other 4 patients relapsed within 3 months. Yamauchi et al.7 found that malignant T cells are more sensitive than normal cells in UVA1 radiation-induced apoptosis. In addition, good therapeutic responses were observed in both medium- and high-dose UVA1. As a consequence, they did not use the high-dose regimen in the treatment of MF. We also observed the therapeutic improvement in all low-, medium- and high-dose UVA1. Thus, the results of our study suggest that the therapeutic effectiveness for MF may be unrelated to UVA1 dose.UVA1 may cause minimal erythema, burning sensation, dryness and hyperpigmentation as short-term side effects. The long-term side effects such as carcinogenesis have so far not been established. Although high doses of UVA1 induced carcinogenesis in some studies, there have been few reported cases of malignant skin cancer9,10. However, based on this observation, a lower cumulative dose from the use of low- and medium-dose UVA1 is likely advantageous compared with a high-dose UVA1 regimen.Our data indicate that UVA1 phototherapy is a well tolerated therapeutic treatment, with excellent results in patients with MF, irrespective of the dose regimen." @default.
• W2035662303 created "2016-06-24" @default.
• W2035662303 creator A5002665547 @default.
• W2035662303 creator A5010004219 @default.
• W2035662303 creator A5037166452 @default.
• W2035662303 creator A5058382490 @default.
• W2035662303 creator A5082447622 @default.
• W2035662303 date "2013-01-01" @default.
• W2035662303 modified "2023-10-02" @default.
• W2035662303 title "Ultraviolet A1 Phototherapy of Mycosis Fungoides" @default.
• W2035662303 cites W1979778164 @default.
• W2035662303 cites W1980507047 @default.
• W2035662303 cites W2005627366 @default.
• W2035662303 cites W2033034542 @default.
• W2035662303 cites W2054955905 @default.
• W2035662303 cites W2075019645 @default.
• W2035662303 cites W2081845325 @default.
• W2035662303 cites W2097858802 @default.
• W2035662303 cites W2110122715 @default.
• W2035662303 cites W2150956753 @default.
• W2035662303 doi "https://doi.org/10.5021/ad.2013.25.1.104" @default.
• W2035662303 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3582907" @default.
• W2035662303 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23463828" @default.
• W2035662303 hasPublicationYear "2013" @default.
• W2035662303 type Work @default.
• W2035662303 sameAs 2035662303 @default.
• W2035662303 citedByCount "4" @default.
• W2035662303 countsByYear W20356623032014 @default.
• W2035662303 countsByYear W20356623032017 @default.
• W2035662303 countsByYear W20356623032020 @default.
• W2035662303 countsByYear W20356623032023 @default.
• W2035662303 crossrefType "journal-article" @default.
• W2035662303 hasAuthorship W2035662303A5002665547 @default.
• W2035662303 hasAuthorship W2035662303A5010004219 @default.
• W2035662303 hasAuthorship W2035662303A5037166452 @default.
• W2035662303 hasAuthorship W2035662303A5058382490 @default.
• W2035662303 hasAuthorship W2035662303A5082447622 @default.
• W2035662303 hasBestOaLocation W20356623032 @default.
• W2035662303 hasConcept C16005928 @default.
• W2035662303 hasConcept C203014093 @default.
• W2035662303 hasConcept C2776960578 @default.
• W2035662303 hasConcept C2777756187 @default.
• W2035662303 hasConcept C2779338263 @default.
• W2035662303 hasConcept C3017420807 @default.
• W2035662303 hasConcept C71924100 @default.
• W2035662303 hasConceptScore W2035662303C16005928 @default.
• W2035662303 hasConceptScore W2035662303C203014093 @default.
• W2035662303 hasConceptScore W2035662303C2776960578 @default.
• W2035662303 hasConceptScore W2035662303C2777756187 @default.
• W2035662303 hasConceptScore W2035662303C2779338263 @default.
• W2035662303 hasConceptScore W2035662303C3017420807 @default.
• W2035662303 hasConceptScore W2035662303C71924100 @default.
• W2035662303 hasIssue "1" @default.
• W2035662303 hasLocation W20356623031 @default.
• W2035662303 hasLocation W20356623032 @default.
• W2035662303 hasLocation W20356623033 @default.
• W2035662303 hasLocation W20356623034 @default.
• W2035662303 hasOpenAccess W2035662303 @default.
• W2035662303 hasPrimaryLocation W20356623031 @default.
• W2035662303 hasRelatedWork W1758669012 @default.
• W2035662303 hasRelatedWork W1946301871 @default.
• W2035662303 hasRelatedWork W1978319863 @default.
• W2035662303 hasRelatedWork W2035662303 @default.
• W2035662303 hasRelatedWork W2093876696 @default.
• W2035662303 hasRelatedWork W2116135478 @default.
• W2035662303 hasRelatedWork W2883726067 @default.
• W2035662303 hasRelatedWork W2901040442 @default.
• W2035662303 hasRelatedWork W4249095656 @default.
• W2035662303 hasRelatedWork W6237367 @default.
• W2035662303 hasVolume "25" @default.
• W2035662303 isParatext "false" @default.
• W2035662303 isRetracted "false" @default.
• W2035662303 magId "2035662303" @default.
• W2035662303 workType "article" @default.